Hints and tips:
Related Special Reports
...Under Emma Walmsley, chief executive since 2017, GSK has struggled to deliver blockbusters: something that has weighed on the £63bn company’s share price....
...The US trustee motion came just two weeks after an individual claimant in the case, Timothy Culberson, filed his own motion to move or dismiss the Sorrento case....
...GSK has spun off its consumer arm, improved its balance sheet and increased investment in R&D. Earnings guidance has risen twice during 2022, helped by strong sales of shingles vaccine Shingrix....
...What gives me pause, however, is that his biggest donor is Timothy Mellon, scion of the famous Pittsburgh family dynasty, and former large contributor to Trump....
...The UK’s share of global pharma R&D has dropped sharply since 2012, from 7.7 per cent to 4.2 per cent in 2020....
...Since 2016, GSK has increased investment in R&D by more than 50 per cent, focusing on the drugs with the most potential to become blockbusters and doubling the number of late-stage assets in the pipeline...
...They include private equity advisers Roger Johnson and Will Aitken-Davies, tax specialists Timothy Lowe and Cian O’Connor and mergers and acquisitions adviser Andreas Philipson, DD’s Will Louch, Arash Massoudi...
...Emma Walmsley, GSK’s chief executive, has raised R&D spending and appointed a new head....
...Other shareholders backed Walmsley....
...“Kjeld said, ‘Make it even larger,’” says Timothy Ahrensbach, director of workplace and employee experience, of the Lego statue....
...Chief executive Emma Walmsley has been looking for the right prescription for investors after sustained underperformance....
...Elliott and other investors questioned whether GSK chief executive Emma Walmsley can improve the pipeline, given her lack of scientific background....
...The only decision before Superior Court Judge Timothy Walmsley on Friday afternoon was whether to allow the men to seek parole after 30 years in prison....
...Barron said that in the past four years GSK had “significantly improved the quality and strength of the pipeline and our overall R&D productivity”, citing 13 major product approvals and more than doubling...
...GSK also stripped his name from its vaccines R&D facility. Slaoui did not comment on Friday....
...Other shareholders have questioned whether Walmsley, who does not have a background in pharmaceutical R&D, is the right person to lead the company. “I’m not a scientist....
...Early successes Walmsley was an unexpected choice to lead the company....
...It’s difficult to know whether GSK’s lagging R&D productivity is bad luck or poor planning, but Elliott is not leaving anything to chance....
...Chief executive Emma Walmsley is under pressure to enthuse shareholders apprehensive about the prospects for future drugs....
...Emma Walmsley, GSK’s chief executive, wrote a letter to employees saying the company had received a letter detailing the allegations in February. She said she was “shocked” and “angry”....
...The president has been accused of dereliction of duty over a R$1.6bn ($320m) deal to acquire 20m jabs of Covaxin....
...It remains to be seen whether the plan will be enough to muffle calls for Walmsley’s resignation....
...GSK boss Emma Walmsley has moved in the same direction: R&D spending in the pharma unit has risen from about 15 per cent of sales to closer to 20 per cent....
...The company will also rename its vaccines R&D facility, which had been named after Slaoui....
...DD is expecting CD&R, which is working with Goldman Sachs, to return with an improved offer....
International Edition